Table 1.
Patient characteristics
| iVRE (n = 18) | Control (n = 18) | P | |
|---|---|---|---|
| Age, yr | 10 (1–62) | 11 (1–63) | Matching criterion |
| Male | 10 (65) | 8 (44) | .48 |
| Donor type | Matching criterion | ||
| Matched sibling | 4 (22) | 4 (22) | |
| Matched unrelated | 1 (6) | 1 (6) | |
| Cord blood | 13 (72) | 13 (72) | |
| Reduced-intensity | 4 (22) | 4 (22) | Matching criterion |
| conditioning | |||
| Diagnosis | Matching criterion | ||
| Malignant* | 11 (61) | 11 (61) | |
| Nonmalignant | 7 (39) | 7 (39) | |
| GVHD prophylaxis | .81 | ||
| CsA based | 16 (89) | 15 (83) | |
| Others | 2 (11) | 3 (17) | |
| Disease risk† | Matching criterion | ||
| Standard | 9 (50) | 9 (50) | |
| High | 2 (11) | 2 (11) | |
| Nonmalignant | 7 (39) | 7 (39) | |
| KPS score <90% | 3 (17) | 2 (11) | .65 |
| HCT-CI | .64 | ||
| 0 | 11 (61) | 9 (50) | |
| 1–2 | 2 (11) | 4 (22) | |
| 3 | 5 (28) | 5 (28) | |
Data are presented as median (range) or n (%).
CsA indicates cyclosporine; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; KPS, Karnofsky Performance Scale.
*
Acute leukemia: 10 patients in the iVRE group and 9 in the control group; Myelodysplastic syndromes/myeloproliferative neoplasms: 1 in the iVRE group and 2 in the control group (P = 1.00).
†
Standard indicates malignancies in first or second complete remission or chronic myeloid leukemia-chronic phase; high indicates other malignancies.